NCT00603642View on ClinicalTrials.gov

P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura

PHASE3CompletedINTERVENTIONAL

Enrollment

34

Participants

Timeline

Start Date

October 1, 2007

Primary Completion Date

April 13, 2009

Study Completion Date

April 13, 2009

Conditions

Idiopathic Thrombocytopenic Purpura

Interventions

DRUG

Placebo

Subcutaneously administered, once a week, for 12 weeks

DRUG

AMG 531

Subcutaneously administered, once a week, for 12 weeks

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY